# US 8,278,315 B2 · Radiotherapy method using x-rays

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,278,315 B2
- Document ID: US8278315B2
- Status: Granted
- Kind: B2
- Application number: 10/651,305
- Filed: 2003-08-28
- Published: 2005-04-14
- Granted: 2012-10-02
- Earliest claimed: 2002-09-05
- Inventors: Chia-Gee Wang
- Web page: https://patentgrep.com/patent/US8278315B2

## CPC

- A61K 41/0085: {Mossbauer effect therapy based on mossbauer effect of a material, i.e. re-emission of gamma rays after absorption of gamma rays by the material; selective radiation therapy, i.e. involving re-emission of ionizing radiation upon exposure to a first ionizing radiation}
- A61K 31/282: Platinum compounds
- A61K 31/704: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)}
- A61K 31/7068: having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K 31/7072: having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
- A61K 41/0038: {Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy (radiotherapy per se A61N5/10)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A method of treating living mammals including humans uses x-rays to disrupt DNA in malfunctioning cells such as cancerous or tumorous cells. A compound comprising a pre-selected element is administered to the mammal so that the compound associates with DNA. Then a localized region of cells which contains the malfunctioning cells is irradiated with line emission x-rays of an energy selected to cause emission of Auger electrons from the pre-selected element of the compound to disrupt DNA proximate to the irradiated pre-selected element. A kit useful for the treatment comprises an x-ray tube capable of emitting monochromatic line emission x-rays and a compound which associates with DNA and has an element which when irradiated emits said Auger electrons.

## Claims

### Claim 1

A method for preferential disruption of malfunctioning cells in a living mammal, which comprises:
(a) administering a compound which associates with DNA in cells of said mammal, said compound comprising a pre-selected element selected from the group consisting of Pt, Ca, Ti, Br, I, Gd, Y and Ru; and then
(b) irradiating a selected region, in which malfunctioning cells having said compound associated with DNA are located, with line emission x-rays from an X-ray tube, said line emission X-rays being of an energy selected to cause emission of Auger electrons from said pre-selected element of said compound in a dose effective to disrupt DNA proximate to the irradiated pre-selected element, said dose for each activation of said X-ray tube being at least about 106 Gy localized with a distance of a few atomic diameters from the pre-selected element, said selected region being a localized region which predominantly contains the malfunctioning cells so as to localize the effects of disrupting DNA to the malfunctioning cells and to minimize the effect on normal cells.

### Claim 2 (depends on 1)

A method according to claim 1, wherein the compound intercalates into the DNA helix.

### Claim 3 (depends on 1)

A method according to claim 1, wherein the compound binds to the DNA.

### Claim 4 (depends on 1)

A method according to claim 1, wherein the compound is substantially non-toxic.

### Claim 5 (depends on 1)

A method according to claim 1, wherein the compound has an affinity for both normal and malfunctioning cells.

### Claim 6 (depends on 5)

A method according to claim 5, wherein the compound is substantially non-toxic.

### Claim 7 (depends on 1)

A method according to claim 1, wherein the compound has a selective affinity for malfunctioning cells.

### Claim 8 (depends on 1)

A method according to claim 1, wherein the compound is selected from the group consisting of annamycin, bromodeoxyuridine, bromodeoxycytosine and iododeoxyuridine

### Claim 9 (depends on 1)

A method according to claim 1, wherein the compound is iododeoxyuridine.

### Claim 10 (depends on 9)

A method according to claim 9, wherein the compound is bromodeoxyuridine.

### Claim 11 (depends on 1)

A method according to claim 1, wherein the compound is a ruthenium compound which binds to or intercalates into DNA.

### Claim 12 (depends on 1)

A method according to claim 1, wherein the compound is cisplatin.

### Claim 13 (depends on 1)

A method according to claim 1, wherein the pre-selected element of the compound is selected from the group consisting of Ru, I and Gd.

### Claim 14 (depends on 1)

A method according to claim 1, wherein the malfunctioning cells of the mammal's body are superficial and the pre-selected element of the compound is Br.

### Claim 15 (depends on 1)

A method according to claim 1, wherein the compound is selected to have a high rate of excretion by normal physiological processes.

### Claim 16 (depends on 1)

A method according to claim 1, wherein the compound is selected for stability against dissociation of the pre-selected element during the time prior to excretion or metabolism of the compound.

### Claim 17 (depends on 1)

A method according to claim 1, wherein an end window transmission x-ray tube producing bright line emission x-rays is used for irradiating.

### Claim 18 (depends on 17)

A method according to claim 17, wherein an e-beam generated in the x-ray tube is focused on a thin target having a thickness selected to provide the line emission x-rays, said thickness not exceeding about 40 μm, said target being inside the tube and functions as part of the end window.

### Claim 19 (depends on 18)

A method according to claim 18, wherein the target and the e-beam energy are selected to provide monochromatic line emission x-rays having an energy above and sufficiently near the K-absorption edge of the pre-selected element of the compound to cause said emission of Auger electrons.

### Claim 20 (depends on 19)

A method according to claim 19, wherein the thin target is selected from the group consisting of Mo, Ag, La, Sr and Tm.

### Claim 21 (depends on 18)

A method according to claim 18, wherein the target and the e-beam energy are selected to provide monochromatic line emission x-rays having an energy above and sufficiently near the L-absorption edge of the pre-selected element of the compound to cause said emission of Auger electrons.

### Claim 22 (depends on 21)

A method according to claim 21, wherein the thin target is Rb.

### Claim 23 (depends on 22)

A method according to claim 22, wherein the pre-selected element of the compound is Pt.

### Claim 24 (depends on 1)

A method according to claim 1, wherein the dose of at least about 106 Gy is released within a distance from the element of the compound of up to about 10 angstroms.

### Claim 25 (depends on 1)

A method according to claim 1, wherein step (b) is repeated at least once.

### Claim 26 (depends on 25)

A method according to claim 25, wherein Auger electrons are released during each repetition of step(b) with a dose of at least about 106Gy.

### Claim 27 (depends on 26)

A method according to claim 26, wherein the dose of at least about 106 Gy is released within a distance from the element of the compound of up to about 10 angstroms.

### Claim 28 (depends on 1)

A method according to claim 1, wherein step (b) is performed on cells removed from the mammal.

### Claim 29 (depends on 28)

A method according to claim 28, wherein after step (b) is performed, the removed cells are returned to the mammal.

### Claim 30 (depends on 28)

A method according to claim 28, wherein after step (b) is performed, the removed cells are transplanted.

### Claim 31 (depends on 1)

A method according to claim 1, wherein step (a) and step (b) are performed on cells removed from the mammal.

### Claim 32 (depends on 31)

A method according to claim 31, wherein after step (b) is performed, the removed cells are returned to the mammal.

### Claim 33 (depends on 31)

A method according to claim 31, wherein after step (b) is performed, the removed cells are transplanted.

### Claim 34 (depends on 1)

A method according to claim 1, wherein the malfunctioning cells are tumor or cancer cells and the mammal is a human.

### Claim 35 (depends on 34)

A method according to claim 34, wherein the compound intercalates into the DNA helix.

### Claim 36 (depends on 34)

A method according to claim 34, wherein the compound binds to the DNA.

### Claim 37 (depends on 34)

A method according to claim 34, wherein the compound is substantially non-toxic.

### Claim 38 (depends on 34)

A method according to claim 34, wherein the compound has an affinity for both normal and cancerous cells.

### Claim 39 (depends on 38)

A method according to claim 38, wherein the compound is substantially non-toxic.

### Claim 40 (depends on 34)

A method according to claim 34, wherein the compound has a selective affinity for cancerous cells.

### Claim 41 (depends on 34)

A method according to claim 34, wherein the compound is selected from the group consisting of annamycin, bromodeoxyuridine, bromodeoxycytosine and iododeoxyuridine.

### Claim 42 (depends on 34)

A method according to claim 34, wherein the compound is iododeoxyuridine.

### Claim 43 (depends on 34)

A method according to claim 34, wherein the compound is bromodeoxyuridine.

### Claim 44 (depends on 34)

A method according to claim 34, wherein the compound is a ruthenium compound which binds to or intercalates into DNA.

### Claim 45 (depends on 34)

A method according to claim 34, wherein the compound is Cisplatin.

### Claim 46 (depends on 1)

A method according to claim 1, wherein the pre-selected element of the compound is selected from the group consisting of Ru, I and Gd.

### Claim 47 (depends on 1)

A method according to claim 1, wherein the cancerous cells of the human's body are superficial and the pre-selected element of the compound is Br.

### Claim 48 (depends on 34)

A method according to claim 34, wherein the compound is selected to have a high rate of excretion by normal physiological processes.

### Claim 49 (depends on 34)

A method according to claim 34, wherein the compound is selected for stability against dissociation of the pre-selected element during the time prior to excretion or metabolism of the compound.

### Claim 50 (depends on 34)

A method according to claim 34, wherein an end window transmission x-ray tube producing bright line emission x-rays is used for irradiating.

### Claim 51 (depends on 50)

A method according to claim 50, wherein an e-beam generated in the x-ray tube is focused on a thin target having a thickness selected to provide the line emission x-rays, said thickness not exceeding about 40 μm, said target being inside the tube and functions as part of the end window.

### Claim 52 (depends on 51)

A method according to claim 51, wherein the target and the e-beam energy are selected to provide monochromatic line emission x-rays having an energy above and sufficiently near the K-absorption edge of the element of the compound to cause said emission of Auger electrons.

### Claim 53 (depends on 52)

A method according to claim 52, wherein the thin target is selected from the group consisting of Mo, Ag, La, Sr and Tm.

### Claim 54 (depends on 51)

A method according to claim 51, wherein the target and the e-beam energy are selected to provide monochromatic line emission x-rays having an energy above and sufficiently near the L-absorption edge of the pre-selected element of the compound to cause said emission of super electrons.

### Claim 55 (depends on 54)

A method according to claim 54, wherein the thin target is Rb.

### Claim 56 (depends on 55)

A method according to claim 55, wherein the pre-selected element of the compound is Pt.

### Claim 57 (depends on 34)

A method according to claim 34, wherein the dose of at least about 106 Gy is released within a distance from the element of the compound of up to about 10 angstroms.

### Claim 58 (depends on 34)

A method according to claim 34, wherein step (b) is repeated at least once.

### Claim 59 (depends on 58)

A method according to claim 58, wherein Auger electrons are released during each repetition of step (b) with a dose of at least about 106 Gy.

### Claim 60 (depends on 59)

A method according to claim 59, wherein the dose of at least about 106 Gy is released within a distance from the element of the compound of up to about 10 angstroms.

### Claim 61 (depends on 1)

A method according to claim 1, wherein the malfunctioning cells are cancerous cells and the mammal is a human, wherein the method comprises:
(a) administering to the human the compound which associates with DNA, in cells of said human, said compound comprising a pre-selected element selected from the group consisting of Br, Ru, I, Gd and Pt; and then
(b) irradiating at least once, by means of an end window transmission x-ray tube, the selected region, in which the cancerous cells having said compound associated with DNA are located, with line emission x-rays of an energy selected to cause emission of Auger electrons from said pre-selected element of said compound in a dose effective to disrupt DNA proximate to the irradiated pre-selected element, said dose for each activation of said x-ray tube being at least about 106 Gy within a distance from the pre-selected element of the compound of up to about 10 angstroms.

### Claim 62 (depends on 61)

A method according to claim 61, wherein the compound intercalates into the DNA helix.

### Claim 63 (depends on 61)

A method according to claim 61, wherein the compound binds to the DNA.

### Claim 64 (depends on 61)

A method according to claim 61, wherein the compound is substantially non-toxic.

### Claim 65 (depends on 61)

A method according to claim 61, wherein the compound has an affinity for both normal and tumorous cells.

### Claim 66 (depends on 65)

A method according to claim 65, wherein the compound is substantially non-toxic.

### Claim 67 (depends on 61)

A method according to claim 61, wherein the compound has a selective affinity for tumorous cells.

### Claim 68 (depends on 61)

A method according to claim 61, wherein the compound is selected from the group consisting of annamycin, bromodeoxyuridine, bromodeoxycytosine and iododeoxyuridine.

### Claim 69 (depends on 61)

A method according to claim 61, wherein the compound is iododeoxyuridine.

### Claim 70 (depends on 61)

A method according to claim 61, wherein the compound is bromodeoxyuridine.

### Claim 71 (depends on 61)

A method according to claim 61, wherein the compound is a ruthenium compound which binds to or intercalates into DNA.

### Claim 72 (depends on 61)

A method according to claim 61, wherein the compound is cisplatin.

### Claim 73 (depends on 61)

A method according to claim 61, wherein the compound is selected to have a high rate of excretion by normal physiological processes.

### Claim 74 (depends on 61)

A method according to claim 61, wherein the compound is selected from stability against dissociation of the pre-selected element time prior to excretion or metabolism of the compound.

### Claim 75 (depends on 61)

A method according to claim 61, wherein an e-beam generated in the x-ray tube is focused on a thin target having a thickness selected to provide the line emission x-rays, said thickness not exceeding about 40 μm, said target being inside the tube and functions as part of the end window.

### Claim 76 (depends on 75)

A method according to claim 75, wherein the target and the e-beam energy are selected to provide monochromatic line emission x-rays having an energy above and sufficiently near the K-absorption edge of the pre-selected element of the compound to cause said emission of Auger electrons.

### Claim 77 (depends on 76)

A method according to claim 76, wherein the thin target is selected from the group consisting of Sr, Ag, La, and Tm.

### Claim 78 (depends on 75)

A method according to claim 75, wherein the target and the e-beam energy are selected to provide monochromatic line emission x-rays having an energy above and sufficiently near the L-absorption edge of the pre-selected element of the compound to cause said emission of Auger electrons.

### Claim 79 (depends on 78)

A method according to claim 78, wherein the thin target is Rb.

### Claim 80 (depends on 79)

A method according to claim 79, wherein the pre-selected element of the compound is Pt.

### Claim 81

A method for treating malfunctioning cells in a living mammal, which comprises:
(a) providing a kit comprising
(1) an x-ray tube having a target comprising a selected metal, said tube being capable of emitting monochromatic line emission x-rays; and (2) a compound comprising a selected element selected from the group consisting of Pt, Ca, Ti, Br, I, Gd, Y and Ru, said compound being capable, upon administration to said mammal, of associating with DNA in cells of said mammal; the selected metal of said target and the selected element of said compound being selected together:
(i) for said metal of said target to emit line emission x-rays having an energy above and near the K-absorption edge or the L-absorption edge of the selected element of said compound, and
(ii) for said element of said compound to release a dose of Auger electrons upon irradiation by said line emission x-rays in a dose effective to disrupt DNA proximate to the irradiated selected element, said dose for each activation of said X-ray tube being at least about 106 Gy localized with a distance of a few atomic diameters from the pre-selected element;
(b) administering the compound to the mammal and
(c) irradiating a selected region, in which malfunctioning cells having said compound associated with DNA are located, with the monochromatic line emission x-rays form the x-ray tube to cause emission of Anger electrons from said pre-selected element of said compound in the dose effective to disrupt DNA proximate to the irradiated pre-selected element.

### Claim 82 (depends on 81)

A method according to claim 81, wherein said x-ray tube is an end window transmission x-ray tube capable of emitting bright, line emission x-rays, said x-ray tube comprising an evacuated, elongated chamber having first and second ends, the first end being connected to a power supply, and within said chamber: electron emitter means near the first end for generating a beam of electrons; an end window transparent to x-rays at the second end, an inner portion of said end window comprising said target; and means for focusing said electron beam on said target.

### Claim 83 (depends on 82)

A method according to claim 82, wherein the target has a thickness selected to provide the line emission x-rays, said thickness not exceeding about 40 μm.

### Claim 84 (depends on 81)

A method according to claim 81, wherein the target is selected from the group consisting of Rb, Mo, Ag, La, Sr and Tm.

### Claim 85 (depends on 81)

A method according to claim 81, wherein the compound is substantially non-toxic.

### Claim 86 (depends on 81)

A method according to claim 81, wherein the compound has an affinity for both normal and malfunctioning cells.

### Claim 87 (depends on 86)

A method according to claim 86, wherein the compound is substantially non-toxic.

### Claim 88 (depends on 81)

A method according to claim 81, wherein the compound has a selective affinity for malfunctioning cells.

### Claim 89 (depends on 81)

A method according to claim 81, wherein the compound is selected from the group consisting of annamycin, bromodeoxyuridine, bromodeoxycytosine and iododeoxyuridine.

### Claim 90 (depends on 81)

A method according to claim 81, wherein the compound is iododeoxyuridine.

### Claim 91 (depends on 81)

A method according to claim 81, wherein the compound is bromodeoxyuridine.

### Claim 92 (depends on 81)

A method according to claim 81, wherein the compound is a ruthenium compound which binds to or intercalates into DNA.

### Claim 93 (depends on 81)

A method according to claim 81, wherein the compound is cisplatin.

### Claim 94 (depends on 81)

A method according to claim 81, wherein the pre-selected element of the compound is selected from the group consisting of Br, Ru, I, Gd and Pt.
